All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F12%3A43901007" target="_blank" >RIV/00064173:_____/12:43901007 - isvavai.cz</a>

  • Result on the web

    <a href="http://dx.doi.org/10.1016/j.crvasa.2011.12.004" target="_blank" >http://dx.doi.org/10.1016/j.crvasa.2011.12.004</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.crvasa.2011.12.004" target="_blank" >10.1016/j.crvasa.2011.12.004</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents

  • Original language description

    The treatment of acute coronary syndromes (ACS) is currently undergoing an interesting evolution due to the introduction of some novel antithrombotic drugs. The available evidence on new oral antiplatelet agents can be summarized as follows: (1) the newdrugs (prasugrel and ticagrelor) are faster, more potent, and more predictable than clopidogrel, and thus prasugrel or ticagrelor may replace clopidogrel in most patients with ACS; (2) prasugrel seems to have a more pronounced acute effect, especially inpatients with acute ST-elevation myocardial infarction (STEMI), and thus prasugrel may be the preferred drug for STEMI, especially for the acute phase; (3) ticagrelor seems to have better secondary preventive effects in the long term, which may be advantageous for patients with acute non-STEMI; and (4) both new drugs have some contraindications or unpleasant side effects and are both substantially more expensive, which may keep a place in therapy for clopidogrel for selected patients

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FA - Cardiovascular diseases including cardio-surgery

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2012

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Cor et Vasa

  • ISSN

    0010-8650

  • e-ISSN

  • Volume of the periodical

    54

  • Issue of the periodical within the volume

    1

  • Country of publishing house

    CZ - CZECH REPUBLIC

  • Number of pages

    7

  • Pages from-to

    "e32"-"e38"

  • UT code for WoS article

  • EID of the result in the Scopus database